A Phase I through Phase III oncology trial costs approximately $56.3 million and lasts for eight years. In 2012, it was reported that a typical protocol has 167 procedures with 11 trial visits over 175 days. In addition, oncology trials often have significant delays, with Phase II trials reporting a delay of over 5 months and Phase III trials reporting an almost 6 and a half month delay. In this final episode of a 3-part series, Senior Patient Recruitment Managers Tricia Buchheit and Lauren Johnson consider how rising costs and complex trial designs effect patient recruitment in oncology trials.
What Does the Future of Childhood Cancer Treatment Look Like?
Now that the RACE for Children Act has come into effect, the drug development industry and patients and their families are optimistic—more drugs will…
Recruiting Solid Tumor Patients in a Complex ADME Trial
PRA's PPS facility in Budapest (PPS-Hungary) was contracted to run an open-label, non-randomized, Phase I study to characterize the mass balance and…
Successes in Phase II Autologous Cellular Therapy Oncology Program
A case study describing two Phase II, multicenter studies assessing the efficacy and safety of an autologous cellular therapy treatment.